The unique and aberrant overexpression and/or activation profiles of RTKs in breast cancers, particularly HER2, hepatocyte growth factor receptor (MET), and EGFR, make them promising prognostic markers and therapeutic targets for disease management. This evidence concerns the gene EGFR and breast carcinoma.